

# Michaël Cerezo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4161207/publications.pdf>

Version: 2024-02-01

39  
papers

5,933  
citations

236925

25  
h-index

315739

38  
g-index

41  
all docs

41  
docs citations

41  
times ranked

14244  
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of a new molecule inducing melanoma cell death: dual AMPK/MELK targeting for novel melanoma therapies. <i>Cell Death and Disease</i> , 2021, 12, 64.	6.3	16
2	Dual Covalent Inhibition of PKM and IMPDH Targets Metabolism in Cutaneous Metastatic Melanoma. <i>Cancer Research</i> , 2021, 81, 3806-3821.	0.9	9
3	Development and <i>in vivo</i> evaluation of fused benzazole analogs of anti-melanoma agent HA15. <i>Future Medicinal Chemistry</i> , 2021, 13, 1157-1173.	2.3	2
4	The Role of mRNA Translational Control in Tumor Immune Escape and Immunotherapy Resistance. <i>Cancer Research</i> , 2021, 81, 5596-5604.	0.9	11
5	Biguanides drugs: Past success stories and promising future for drug discovery. <i>European Journal of Medicinal Chemistry</i> , 2021, 224, 113726.	5.5	15
6	Arylbiamidines: synthesis and structural studies en route to anticancer applications. <i>New Journal of Chemistry</i> , 2021, 45, 11893-11897.	2.8	2
7	Cancer cell metabolic reprogramming: a keystone for the response to immunotherapy. <i>Cell Death and Disease</i> , 2020, 11, 964.	6.3	61
8	Sulfonylguanidine Derivatives as Potential Antimelanoma Agents. <i>ChemMedChem</i> , 2020, 15, 1113-1117.	3.2	9
9	The GRP78/BiP inhibitor HA15 synergizes with mitotane action against adrenocortical carcinoma cells through convergent activation of ER stress pathways. <i>Molecular and Cellular Endocrinology</i> , 2018, 474, 57-64.	3.2	33
10	Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype. <i>Genes and Development</i> , 2018, 32, 448-461.	5.9	69
11	Translational control of tumor immune escape via the eIF4E-STAT1-PD-L1 axis in melanoma. <i>Nature Medicine</i> , 2018, 24, 1877-1886.	30.7	180
12	Metformin: Focus on Melanoma. <i>Frontiers in Endocrinology</i> , 2018, 9, 472.	3.5	40
13	E2F1 inhibition mediates cell death of metastatic melanoma. <i>Cell Death and Disease</i> , 2018, 9, 527.	6.3	32
14	Metformin monotherapy in melanoma: a pilot, open-label, prospective, and multicentric study indicates no benefit. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 378-380.	3.3	23
15	Structure activity relationship and optimization of N-(3-(2-aminothiazol-4-yl)aryl)benzenesulfonamides as anti-cancer compounds against sensitive and resistant cells. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 2192-2196.	2.2	11
16	New anti-cancer molecules targeting HSPA5/BIP to induce endoplasmic reticulum stress, autophagy and apoptosis. <i>Autophagy</i> , 2017, 13, 216-217.	9.1	57
17	Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges. <i>Medicinal Research Reviews</i> , 2017, 37, 98-148.	10.5	92
18	Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor Resistance. <i>Cancer Cell</i> , 2016, 29, 805-819.	16.8	201

#	ARTICLE	IF	CITATIONS
19	Discovery and Optimization of N-(4-(3-Aminophenyl)thiazol-2-yl)acetamide as a Novel Scaffold Active against Sensitive and Resistant Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 8276-8292.	6.4	20
20	Targeting BIP to induce Endoplasmic Reticulum stress and cancer cell death. <i>Oncoscience</i> , 2016, 3, 306-307.	2.2	7
21	Mechanism of melanoma cells selective apoptosis induced by a photoactive NADPH analogue. <i>Oncotarget</i> , 2016, 7, 82804-82819.	1.8	14
22	Is it time to test biguanide metformin in the treatment of melanoma?. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 8-20.	3.3	27
23	Increased CD271 expression by the NF- $\kappa$ B pathway promotes melanoma cell survival and drives acquired resistance to BRAF inhibitor vemurafenib. <i>Cell Discovery</i> , 2015, 1, 15030.	6.7	56
24	The PRKAA1/AMPK $\pm$ 1 pathway triggers autophagy during CSF1-induced human monocyte differentiation and is a potential target in CMML. <i>Autophagy</i> , 2015, 11, 1114-1129.	9.1	86
25	Tumour-derived SPARC drives vascular permeability and extravasation through endothelial VCAM1 signalling to promote metastasis. <i>Nature Communications</i> , 2015, 6, 6993.	12.8	151
26	Autophagy and SQSTM1 on the RHOA(d) again. <i>Autophagy</i> , 2014, 10, 201-208.	9.1	32
27	Inhibition of Melanogenesis by the Antidiabetic Metformin. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2589-2597.	0.7	53
28	The P2Y6-AMPK Pathway Triggers Autophagy during CSF-1-Induced Human Monocyte Differentiation and Is a Potential Target in CMML. <i>Blood</i> , 2014, 124, 4347-4347.	1.4	0
29	Autophagy Plays a Critical Role in the Degradation of Active RHOA, the Control of Cell Cytokinesis, and Genomic Stability. <i>Cancer Research</i> , 2013, 73, 4311-4322.	0.9	88
30	Metformin Blocks Melanoma Invasion and Metastasis Development in AMPK/p53-Dependent Manner. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1605-1615.	4.1	176
31	Mitochondrial oxidative stress is the achille's heel of melanoma cells resistant to Braf-mutant inhibitor. <i>Oncotarget</i> , 2013, 4, 1986-1998.	1.8	145
32	Abstract A224: Autophagy and SQSTM1 on the RHOA(d) again.. , 2013, , .		0
33	Aurora B Is Regulated by the Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase (MAPK/ERK) Signaling Pathway and Is a Valuable Potential Target in Melanoma Cells. <i>Journal of Biological Chemistry</i> , 2012, 287, 29887-29898.	3.4	70
34	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	9.1	3,122
35	The Epithelial-Mesenchymal Transition (EMT) Regulatory Factor SLUG (SNAI2) Is a Downstream Target of SPARC and AKT in Promoting Melanoma Cell Invasion. <i>PLoS ONE</i> , 2012, 7, e40378.	2.5	176
36	Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. <i>Cell Death and Disease</i> , 2011, 2, e199-e199.	6.3	250

#	ARTICLE	IF	CITATIONS
37	Senescent cells develop a PARP-1 and nuclear factor- $\kappa$ B-associated secretome (PNAS). <i>Genes and Development</i> , 2011, 25, 1245-1261.	5.9	223
38	In Vitro and In Vivo Anti-Melanoma Effects of Ciglitazone. <i>Journal of Investigative Dermatology</i> , 2009, 129, 1208-1218.	0.7	51
39	A Unique PPAR $\delta$ Ligand with Potent Insulin-Sensitizing yet Weak Adipogenic Activity. <i>Molecular Cell</i> , 2001, 8, 737-747.	9.7	279